The utility of recruitment incentives in early Alzheimer's disease trials

Authors:
Open Access
Publisher website
Google Scholar
Abstract
INTRODUCTION: Amid recent approvals, early Alzheimer's disease (AD) remains an active area of treatment development.METHODS: We performed a conjoint experiment to compare preferences among 26 patients with mild cognitive impairment for four trial features including designs incorporating active aducanumab‐control (vs. placebo), returning tau positron emission tomography (PET) results (vs. no disclosure), remote study partner participation (vs. in person), and increased risk of brain swelling (vs. lower risk). We used a generalized estimating equation to model the utility of factor levels.RESULTS: Returning tau PET results had the highest utility (est: 0.47; 95% confidence interval [CI]: 0.13, 0.81; P = 0.007); remote study partner participation showed a similar trend (est: 0.29; 95% CI: −0.05, 0.63; P = 0.097). Trials with active‐controlled design (est: 0.01; 95% CI: −0.33, 0.35; P = 0.956) did not demonstrate utility and higher risk of brain swelling had negative utility (est: −0.64; 95% CI: −0.99, −0.30; P < 0.001).DISCUSSION: Returning additional biomarker results may increase willingness to enroll in early AD trials.Highlights: We compared mild cognitive impairment participant preferences for four trial design features. Returning tau positron emission tomography results had the highest utility. Remote study partner participation showed a positive, albeit non‐significant, trend. No utility was observed for an active aducanumab‐control design.
Funding Information
  • BrightFocus Foundation (A2018405S, NIA P30 AG066519)

This publication has 14 references indexed in Scilit: